BRIEF-Janssen's Imbruvica receives CHMP opinion for use in lymphocytic leukaemia patients
April 29, 2016 at 09:54 AM EDT
* Janssen's Imbruvica (ibrutinib) receives positive CHMP opinion for expanded use in previously untreated chronic lymphocytic leukaemia patients